However, the returns for some of the large pharmaceutical companies were lower than that of the broader markets, with the S&P 500 index rising 54% over the same period. Furthermore, it is the consumer healthcare business with a higher risk from legal issues pertaining to the talc powder. The S&P500 has now entered the bear market territory with rising concerns of slowing economic growth given the high inflation, Fed action, and supply chain disruptions.